AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

The lung-cancer drug Datroway, being jointly developed by AstraZeneca and Daiichi Sankyo, has been approved in the U.S. to treat adult patients with non-small cell lung cancer. "AstraZeneca's Datroway ...

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...